Cargando…
Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira)
INTRODUCTION: Combination therapy with both basal insulin (BI) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is an effective treatment in patients with uncontrolled type 2 diabetes mellitus (T2DM). The recent development and release of a fixed-ratio combination of slow-release insulin deg...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843811/ https://www.ncbi.nlm.nih.gov/pubmed/33104959 http://dx.doi.org/10.1007/s13300-020-00945-4 |
_version_ | 1783644213108277248 |
---|---|
author | Zenari, Luciano Da Porto, Andrea De Moliner, Lorena Lugli, Francesca Guazzoni, Valeria Groppelli, Gloria Molteni, Laura Bracaccia, Massimo Frison, Vera Simioni, Natalino Bonsembiante, Barbara Miranda, Cesare Lapolla, Annunziata |
author_facet | Zenari, Luciano Da Porto, Andrea De Moliner, Lorena Lugli, Francesca Guazzoni, Valeria Groppelli, Gloria Molteni, Laura Bracaccia, Massimo Frison, Vera Simioni, Natalino Bonsembiante, Barbara Miranda, Cesare Lapolla, Annunziata |
author_sort | Zenari, Luciano |
collection | PubMed |
description | INTRODUCTION: Combination therapy with both basal insulin (BI) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is an effective treatment in patients with uncontrolled type 2 diabetes mellitus (T2DM). The recent development and release of a fixed-ratio combination of slow-release insulin degludec and the GLP-1RA liraglutide (IDegLira) represents an improvement to this therapy. We have conducted a real-world evidence study in Italian patients with T2DM to evaluate whether the encouraging clinical trial results obtained with IDegLira, which became available in Italy in January 2018, can be confirmed in Italian clinical practice. METHODS: This was a multicenter, retrospective, observational study in patients with T2DM treated with IDegLira from January to December 2018. Prior to the initiation of IDegLira therapy, patients were treated with BI with or without one or more concomitant oral antidiabetic drugs (BOT group) or according to the basal bolus protocol (BI and rapid-acting insulin treatment; BB group). RESULTS: A total of 244 patients were included in the present study, of whom 186 were in the BOT group and 58 in the BB group. Following the switch to IDegLira therapy, glycemic control improved in both groups, with significant reductions in glycated hemoglobin after 6 and 12 months of treatment in the BOT group and after 6 months of treatment in the BB group. No gain in body weight and body mass index and reductions in fasting plasma glucose and number of concomitant diabetic medications (in BOT patients) were observed. All results obtained during the study were achieved at a moderate dose of IDegLira. CONCLUSION: The findings from this study show that in a real-world setting, the switch to IDegLira treatment is a valid option for patients who are failing to achieve glycemic control targets and/or struggling with the side effects, such as weight gain and hypoglycemia, of other insulin therapies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-020-00945-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7843811 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-78438112021-01-29 Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira) Zenari, Luciano Da Porto, Andrea De Moliner, Lorena Lugli, Francesca Guazzoni, Valeria Groppelli, Gloria Molteni, Laura Bracaccia, Massimo Frison, Vera Simioni, Natalino Bonsembiante, Barbara Miranda, Cesare Lapolla, Annunziata Diabetes Ther Original Research INTRODUCTION: Combination therapy with both basal insulin (BI) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is an effective treatment in patients with uncontrolled type 2 diabetes mellitus (T2DM). The recent development and release of a fixed-ratio combination of slow-release insulin degludec and the GLP-1RA liraglutide (IDegLira) represents an improvement to this therapy. We have conducted a real-world evidence study in Italian patients with T2DM to evaluate whether the encouraging clinical trial results obtained with IDegLira, which became available in Italy in January 2018, can be confirmed in Italian clinical practice. METHODS: This was a multicenter, retrospective, observational study in patients with T2DM treated with IDegLira from January to December 2018. Prior to the initiation of IDegLira therapy, patients were treated with BI with or without one or more concomitant oral antidiabetic drugs (BOT group) or according to the basal bolus protocol (BI and rapid-acting insulin treatment; BB group). RESULTS: A total of 244 patients were included in the present study, of whom 186 were in the BOT group and 58 in the BB group. Following the switch to IDegLira therapy, glycemic control improved in both groups, with significant reductions in glycated hemoglobin after 6 and 12 months of treatment in the BOT group and after 6 months of treatment in the BB group. No gain in body weight and body mass index and reductions in fasting plasma glucose and number of concomitant diabetic medications (in BOT patients) were observed. All results obtained during the study were achieved at a moderate dose of IDegLira. CONCLUSION: The findings from this study show that in a real-world setting, the switch to IDegLira treatment is a valid option for patients who are failing to achieve glycemic control targets and/or struggling with the side effects, such as weight gain and hypoglycemia, of other insulin therapies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-020-00945-4) contains supplementary material, which is available to authorized users. Springer Healthcare 2020-10-26 2021-01 /pmc/articles/PMC7843811/ /pubmed/33104959 http://dx.doi.org/10.1007/s13300-020-00945-4 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Zenari, Luciano Da Porto, Andrea De Moliner, Lorena Lugli, Francesca Guazzoni, Valeria Groppelli, Gloria Molteni, Laura Bracaccia, Massimo Frison, Vera Simioni, Natalino Bonsembiante, Barbara Miranda, Cesare Lapolla, Annunziata Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira) |
title | Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira) |
title_full | Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira) |
title_fullStr | Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira) |
title_full_unstemmed | Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira) |
title_short | Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira) |
title_sort | real-world evaluation of glycemic outcomes and extra-glycemic parameters in diabetic patients treated with the combined formulation degludec–liraglutide (ideglira) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843811/ https://www.ncbi.nlm.nih.gov/pubmed/33104959 http://dx.doi.org/10.1007/s13300-020-00945-4 |
work_keys_str_mv | AT zenariluciano realworldevaluationofglycemicoutcomesandextraglycemicparametersindiabeticpatientstreatedwiththecombinedformulationdegludecliraglutideideglira AT daportoandrea realworldevaluationofglycemicoutcomesandextraglycemicparametersindiabeticpatientstreatedwiththecombinedformulationdegludecliraglutideideglira AT demolinerlorena realworldevaluationofglycemicoutcomesandextraglycemicparametersindiabeticpatientstreatedwiththecombinedformulationdegludecliraglutideideglira AT luglifrancesca realworldevaluationofglycemicoutcomesandextraglycemicparametersindiabeticpatientstreatedwiththecombinedformulationdegludecliraglutideideglira AT guazzonivaleria realworldevaluationofglycemicoutcomesandextraglycemicparametersindiabeticpatientstreatedwiththecombinedformulationdegludecliraglutideideglira AT groppelligloria realworldevaluationofglycemicoutcomesandextraglycemicparametersindiabeticpatientstreatedwiththecombinedformulationdegludecliraglutideideglira AT moltenilaura realworldevaluationofglycemicoutcomesandextraglycemicparametersindiabeticpatientstreatedwiththecombinedformulationdegludecliraglutideideglira AT bracacciamassimo realworldevaluationofglycemicoutcomesandextraglycemicparametersindiabeticpatientstreatedwiththecombinedformulationdegludecliraglutideideglira AT frisonvera realworldevaluationofglycemicoutcomesandextraglycemicparametersindiabeticpatientstreatedwiththecombinedformulationdegludecliraglutideideglira AT simioninatalino realworldevaluationofglycemicoutcomesandextraglycemicparametersindiabeticpatientstreatedwiththecombinedformulationdegludecliraglutideideglira AT bonsembiantebarbara realworldevaluationofglycemicoutcomesandextraglycemicparametersindiabeticpatientstreatedwiththecombinedformulationdegludecliraglutideideglira AT mirandacesare realworldevaluationofglycemicoutcomesandextraglycemicparametersindiabeticpatientstreatedwiththecombinedformulationdegludecliraglutideideglira AT lapollaannunziata realworldevaluationofglycemicoutcomesandextraglycemicparametersindiabeticpatientstreatedwiththecombinedformulationdegludecliraglutideideglira |